Summary: A lengthy treatment process, coupled with weighty risks for recipients to consider, has resulted in plodding adoption of Casgevy and Lyfgenia during their first year on market.
Summary: Harvard geneticist David Sinclair aims to develop treatments for aging, but his companies have struggled to deliver
Summary: Following its second workforce reduction this year, Carisma retains 44 full-time employees while focusing on developing treatments for fibrosis, oncology, and autoimmune diseases.
Summary: GSK plans to relaunch Blenrep, previously withdrawn after a failed confirmatory study, leveraging its survival advantage over J&J’s Darzalex.
Summary: The facility, known as Modulus, can switch between making different vaccines or treatments in a matter of days.
